Haemonetics reported excellent Q2 results, says Barrington Barrington believes that Haemonetics' base business continues to be strong while its integration of PALL is proceeding better than expected. The firm notes that it raised its target on the stock to $88 from $79 yesterday. It reiterates an Outperform rating on the stock.
News For HAE From The Last 14 Days
Check below for free stories on HAE the last two weeks.